Parkinson’s patients who carry PARK2 mutations, which are associated with dysfunction in the mitochondrial system and have a more restricted distribution of neuropathology, perform better in cognitive tests than patients with sporadic Parkinson’s disease (Alcalay et al., 2014). The gene discussed is PRKN; the disease is Parkinson disease.